The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials
Authors:
- 24 October 2011
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 20 (12) , 1677-1684
Abstract
(2011). The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opinion on Investigational Drugs: Vol. 20, No. 12, pp. 1677-1684.Keywords
This publication has 54 references indexed in Scilit:
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- Fyn Is Downstream of the HGF/MET Signaling Axis and Affects Cellular Shape and Tropism in PC3 CellsClinical Cancer Research, 2011
- HGF-independent potentiation of EGFR action by c-MetOncogene, 2011
- Distinct Interactions Between c-Src and c-Met in Mediating Resistance to c-Src Inhibition in Head and Neck CancerClinical Cancer Research, 2011
- Efficacy of c-Met inhibitor for advanced prostate cancerBMC Cancer, 2010
- Stromal Hyaluronan Interaction with Epithelial CD44 Variants Promotes Prostate Cancer Invasiveness by Augmenting Expression and Function of Hepatocyte Growth Factor and Androgen ReceptorJournal of Biological Chemistry, 2010
- Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1α in non-small cell lung cancer cellsOncogene, 2010
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007
- Direct Interaction of Focal Adhesion Kinase (FAK) with Met Is Required for FAK To Promote Hepatocyte Growth Factor-Induced Cell InvasionMolecular and Cellular Biology, 2006
- Scatter factor is a fibroblast-derived modulator of epithelial cell mobilityNature, 1987